The FDA on Saturday authorized the emergency use of an experimental antibody treatment from Regeneron for mild and moderate cases of the coronavirus that was given to President Donald Trump in October.
The drug is a cocktail of two monoclonal antibodies that mimic the body’s natural defenses against the virus. The emergency authorization allows the drug to be used in adults and children over the age of 12 with mild to moderate Covid-19 symptoms who are at high risk of progressing to severe disease or requiring hospitalization. The treatment is not authorized for patients who are hospitalized due to the coronavirus or who require oxygen therapy.
Regeneron has published data from a late-stage trial showing that the antibody reduces the amount of virus in a person’s body, and may speed recoveries.
“Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” FDA Commissioner Stephen Hahn said in a press release.
President Donald Trump, who received the Regeneron antibody cocktail during his bout with Covid-19 in early October and referred to the drug as a “cure,” pressured the FDA to quickly authorize such treatments. Eli Lilly also won an emergency authorization for its antibody drug earlier this month.The authorizations may make it more difficult for Regeneron and Lilly to complete their ongoing studies, and for trials of other antibody treatments to attract participants.
Content source:
Please Check out file at the following link
Steam Biological Indicator 10^5 (RRS 14-21110)
Hospital infections affect 14 out of every 100 patients admitted
